Focus

CureVac

LATEST

Business
Business

Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims

Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims
|
Economy
Economy

BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims

BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims
|
Companies
Companies

CureVac Files Patent Lawsuit in Germany Against BioNTech

CureVac Files Patent Lawsuit in Germany Against BioNTech
|
Vaccines & Safety
Vaccines & Safety

CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout

CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout
|
Business
Business

Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims

Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims
|
Economy
Economy

BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims

BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims
|
Companies
Companies

CureVac Files Patent Lawsuit in Germany Against BioNTech

CureVac Files Patent Lawsuit in Germany Against BioNTech
|
Vaccines & Safety
Vaccines & Safety

CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout

CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout
|